Diabetes management: a case-based discussion
Date Published:
Wednesday, September 22, 2021
Duration:
18:41
Dr Rinki Murphy uses a case-based approach to diabetes management incorporating the new Diabetes Management Guidance and discusses where the newly funded dulaglutide fits.
Topics:
- 00:00 Intro
- 01:04 Case intro
- 01:56 Treating to target to minimise diabetic complications and maximise longevity
- 02:59 How do we optimise his management?
- 06:47 If we were to add in a new medication, what would it be and why?
- 08:53 Do we need to down titrate existing medications and up titrate new ones?
- 10:57 What monitoring do we need to do?
- 12:00 What are the expected benefits of this for our case?
- 12:47 What if our case was already taking insulin? How would this change things? Do we stop insulin?
- 14:06 Fast forward a decade. What would we need to do now?
- 15:58 Special authority criteria
- 17:14 Take-home messages
Take-home messages
|
Resources
- Best Practice e-Journal - Diabetes Special Edition bpacnz (2021)
- Trulicity (dulaglutide 1.5 mg/0.5 mL) solution for injection NZ Data Sheet (2021)
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (2019)
- Dulaglutide for type 2 diabetes. Aust Prescr (2018)
- Type 2 Diabetes Management Guidance. NZSSD and MOH (2021)
- Decision to fund two new medicines for type 2 diabetes - Amended with Q&A PHARMAC (2021)
Presenter
Rinki Murphy
Diabetes Physician
Rinki is an Associate Professor in Medicine at the University of Auckland and Principle investigator at the Maurice Wilkins Centre for Biodiscovery. She is a diabetologist at Auckland and Counties Manukau DHBs.
This podcast episode is supported by Lilly:
This presentation is intended for qualified health practitioners professional development and should not be relied upon for any other purpose. Any opinions offered are those of the presenter or other speaker and do not necessarily represent the views of Goodfellow Unit.